Seems pretty clear that the FDA came back with additional questions. Well......that sucks. Hopefully the questions were minor, and can be addressed in a relatively short amount of time.

Not exactly what we were looking for, but it will be good to get further color from Jay on this, as well as hear about his approach to the next HIV trial and business development.